Sunitinib and other targeted therapies for renal cell carcinoma.
Sunitinib and other targeted therapies for renal cell carcinoma.
复制标题
DOI：
10.1038/sj.bjc.6606061
复制
发表时间：
2011-03-01
影响因子：
8.8
通讯作者：
中科院分区：
文献类型：
--
作者：
靶向治疗从根本上改变了转移性肾癌的治疗方式。目前有六种药物在这种情况下获得许可，其他几种药物正在评估中。舒尼替尼是目前在一线治疗中使用最广泛的药物，具有令人印象深刻的疗效和既定的毒性特征。然而，随着进一步的随机研究报告和新药的问世，这种情况可能会改变。在这篇综述中，我们讨论了我们目前对肾癌靶向治疗的理解。我们还讨论了我们的知识不完整的领域，包括相关生物标记物的识别和耐药机制。最后，我们将描述未来几年将报告的临床研究的主要领域。
Targeted therapy has radically altered the way metastatic renal cancer is treated. Six drugs are now licensed in this setting, with several other agents under evaluation. Sunitinib is currently the most widely used in the first line setting with impressive efficacy and an established toxicity profile. However, as further randomised studies report and as newer drugs become available this may change. In this review, we address our current understanding of targeted therapy in renal cancer. We also discuss areas in which our knowledge is incomplete, including the identification of correlative biomarkers and mechanisms of drug resistance. Finally, we will describe the major areas of clinical research that will report over the next few years.
登录
查看更多内容
影响因子：
45.3
作者：
Rini, Brian I.;Michaelson, M. Dror;George, Daniel J.
通讯作者：
George, Daniel J.
影响因子：
6.6
作者：
Na, X;Wu, G;Messing, EM
通讯作者：
Messing, EM
影响因子：
168.9
作者：
Escudier, Bernard;Pluzanska, Anna;Moore, Nicola
通讯作者：
Moore, Nicola
影响因子：
45.3
作者：
Rini, Brian I.;Wilding, George;Dutcher, Janice P.
通讯作者：
Dutcher, Janice P.
影响因子：
6.2
作者：
Motzer, Robert J.;Bukowski, Ronald M.;Kaftan, Michael W.
通讯作者：
Kaftan, Michael W.